ArticleBlood cancer journal2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients.
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The association between allostatic load and monoclonal gammopathy of undetermined significance (MGUS).British journal of haematology · 2026Article
- Disparities in Allostatic Load Among Different Races: A Comprehensive Scoping Review.Journal of racial and ethnic health disparities · 2025Review
- National Cancer Institute Cancer Treatment Tolerability Consortium: Current status and future directions.Cancer · 2025Article
- Review
- Neighborhood disadvantage and multiple myeloma incidence in the Black Women's Health Study.International journal of epidemiology · 2025Article
- The Longitudinal Relationship Between Allostatic Load and Multimorbidity Among Older Americans.Geriatrics (Basel, Switzerland) · 2025Article
- Allostatic load and cancer risk, progression, and mortality in epidemiologic studies.American journal of epidemiology · 2025Article
- Cumulative deficits frailty index and relationship status predict survival in multiple myeloma.Blood advances · 2025Article
- Proximity to cancer rehabilitation and exercise oncology by geography, race, and socioeconomic status.Cancer · 2025Article
- The influence of non-cancer-related risk factors on the development of cancer-related lymphedema: a rapid review.Medical oncology (Northwood, London, England) · 2024Review
- Neighborhood-level deprivation and survival in lung cancer.BMC cancer · 2024Article
- Association Between Uveal Melanoma and Allostatic Load.Anticancer research · 2024Article
- The Implications of Racialized Economic Segregation and Allostatic Load on Mortality in Patients with Breast Cancer.Annals of surgical oncology · 2024Article
- Higher Stress in Oncology Patients is Associated With Cognitive and Evening Physical Fatigue Severity.Journal of pain and symptom management · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The objective of this study is to examine the association between neighborhood socioeconomic status (nSES) and baseline allostatic load (AL) and clinical trial endpoints in patients enrolled in the E1A11 therapeutic trial in multiple myeloma (MM). Study endpoints were symptom burden (pain, fatigue, and bother) at baseline and 5.5 months, non-completion of induction therapy, overall survival (OS) and progression-free survival (PFS). Multivariable logistic and Cox regression examined associations between nSES, AL and patient outcomes. A 1-unit increase in baseline AL was associated with greater odds of high fatigue at baseline (adjusted OR [95% CI] = 1.21 [1.08-1.36]) and a worse OS (adjusted hazard ratio, [95% CI] = 1.21 [1.06-1.37]). High nSES was associated with worse baseline bother (middle OR = 4.22 [1.11-16.09] and high 4.49 [1.16-17.43]) compared to low nSES. There was no association between AL or nSES and symptom burden at 5.5 months, non-completion of induction therapy or PFS. Additionally, there was no association between nSES and OS. AL may have utility as a predictive marker for OS among patients with MM and may allow individualization of treatment. Future studies should standardize and validate AL patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.